Sumit Biosciences Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
- Paid Up Capital ₹ 1.77 Cr
- Company Age 36 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.14 Cr
- Revenue Growth 161.10%
- Profit Growth 142.82%
- Ebitda 212.39%
- Net Worth 17.41%
- Total Assets 7.62%
About Sumit Biosciences
Sumit Biosciences Private Limited (SBPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 March 1988 and has a history of 36 years and 11 months. Its registered office is in Mumbai, Maharashtra, India.
The Corporate was formerly known as Sumit Exports And Trades Private Limited. The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.77 Cr.
The company has closed loans amounting to ₹2.14 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Poonam Mital, Jayaraj Dangre, and Sujata Rajindar serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U51900MH1988PTC046424
-
Company No.
046424
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
08 Mar 1988
-
Date of AGM
29 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
What products or services does Sumit Biosciences Private Limited offer?
Sumit Biosciences Private Limited offers a wide range of products and services, including Electrodiagnostic Instruments, Diagnostic Instruments, Rapid Test Kit, Diagnostic Test Kit, Anti Cancer Medicines, Monoclonal Antibodies.
Who are the key members and board of directors at Sumit Biosciences?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Poonam Mital
|
Director | 08-Apr-2023 | Current |
|
Jayaraj Dangre
|
Director | 30-Jul-2005 | Current |
|
Sujata Rajindar
|
Director | 15-Jul-1995 | Current |
Financial Performance of Sumit Biosciences.
Sumit Biosciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 161.1% increase. The company also saw a substantial improvement in profitability, with a 142.82% increase in profit. The company's net worth Soared by an impressive increase of 17.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sumit Biosciences?
In 2023, Sumit Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Inditalia Refcon LtdSujata Rajindar is a mutual person
-
Sedia Biosciences (India) Private LimitedSujata Rajindar is a mutual person
Charges (Loans)
₹0
₹2.14 Cr
Charges Breakdown by Lending Institutions
- Uco Bank : 1.64 Cr
- Kokan Merchantile Co-Operative Bank Ltd. : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jun 2021 | Uco Bank | ₹4.61 M | Satisfied |
| 18 Jun 2019 | Uco Bank | ₹4.61 M | Satisfied |
| 26 Dec 2017 | Uco Bank | ₹1.20 M | Satisfied |
| 13 Nov 2017 | Uco Bank | ₹1.50 M | Satisfied |
| 25 Aug 2016 | Uco Bank | ₹4.50 M | Satisfied |
How Many Employees Work at Sumit Biosciences?
Unlock and access historical data on people associated with Sumit Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sumit Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sumit Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
